Boston Scientific Corporation (ETR:BSX)
Germany · Delayed Price · Currency is EUR | Market Cap | 62.53B -53.6% |
| Revenue (ttm) | 18.38B +13.5% |
| Net Income | 3.22B +46.7% |
| EPS | 2.16 +46.9% |
| Shares Out | n/a |
| PE Ratio | 19.44 |
| Forward PE | 15.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,337 |
| Open | 42.42 |
| Previous Close | 42.95 |
| Day's Range | 42.17 - 43.48 |
| 52-Week Range | 37.03 - 92.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatogra... [Read more]
Financial Performance
In 2025, Boston Scientific's revenue was $20.07 billion, an increase of 19.87% compared to the previous year's $16.75 billion. Earnings were $2.90 billion, an increase of 56.40%.
Financial numbers in USD Financial StatementsNews
Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results
MARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026.
Penumbra, Inc. Reports Second Quarter 2026 Financial Results
ALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026.
Boston Scientific Earnings Call Transcript: Q2 2026
Q2 2026 saw 7% organic sales growth and 15% adjusted EPS growth, exceeding guidance. Full-year 2026 outlook was revised down due to WATCHMAN and EP headwinds, with organic revenue now expected to grow 5%-6% and adjusted EPS 7%-8%. Restructuring and new launches are set to drive recovery by 2028.
Boston Scientific Slides: Q2 2026
Boston Scientific has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Boston Scientific Earnings release: Q2 2026
Boston Scientific released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Boston Scientific Quarterly report: Q2 2026
Boston Scientific has published its Q2 2026 quarterly earnings report on July 29, 2026.
Boston Scientific Cuts Outlook Ahead of Restructuring
Boston Scientific logged higher second-quarter results and cut its full-year outlook as it begins a new restructuring plan announced earlier this week.
Boston Scientific trims annual profit forecast on softer Watchman device demand
Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.
Boston Scientific announces results for second quarter 2026
MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported b...
Boston Scientific unveils new restructuring plan, expects job cuts
Boston Scientific's board has approved a new company-wide restructuring plan aimed at cutting costs and to better position the company for future growth, the medical device maker said in a regulator...
Belo Sun Announces Management Transition
TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTCQX: BSXGF) (the “Company” or “Belo Sun”) today announced a change to its in-country executive leadership team as the Vol...
Belo Sun Announces Corporate Update
TORONTO, June 01, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (TSX: BSX) (OTC: BSXGF) (the “Company” or “Belo Sun”) provides the following updates regarding a recent petition filed by the Brazilian...
Boston Scientific slides after flagging slowdown in Watchmen heart device usage
Boston Scientific shares fell about 12% on Wednesday to their lowest in more than two years, after the medical device maker flagged declining usage of its heart disease device.
Boston Scientific Transcript: Bernstein 42nd Annual Strategic Decisions Conference
Management reaffirmed confidence in achieving margin and EPS growth despite lowering 2024 guidance due to challenges in WATCHMAN, EP, and urology. Key growth drivers include new product launches, the Penumbra acquisition, and innovation in TAVR and mapping. Robust pipeline and disciplined capital allocation support a positive long-term outlook.
Belo Sun Announces 2026 Shareholder Meeting Voting Results and Corporate Update
TORONTO, May 26, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX:BSX OTCQX:BSXGF) today is pleased to announce that each of the six individuals nominated for election...
Belo Sun Provides Update on Ongoing Proceedings Before TRF-1
TORONTO, May 21, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX, OTCQX: BSXGF) is pleased to provide an update regarding hearings held yesterday before the 6th ...
FRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpoints
Late-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery disease MARLBOROUGH, Mass. ...
Boston Scientific invests $1.5 billion in MiRus with option to buy heart-valve business
U.S. medical device maker Boston Scientific said on Monday it has invested $1.5 billion in privately held MiRus LLC in return for a 34% equity stake and potential access to the startup's heart-valve...
Boston Scientific enters into $2 billion accelerated share repurchase agreement
MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase ...
Boston Scientific Slides: Acquisition presentation
Boston Scientific has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Boston Scientific announces strategic investment in MiRus LLC
Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ -- Boston Scientif...
Belo Sun to Commence Technical Studies on Volta Grande Gold Project
TORONTO, May 12, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or “Company”) (TSX: BSX, OTCQB: BSXGF) today announces the commencement of technical studies relating to its Volta Grande Go...
US FDA issues recall of Boston Scientific heart devices
Boston Scientific has issued an urgent recall to correct several heart devices after the U.S. Food and Drug Administration classified the action as its most serious recall, the regulator said on Thu...
Belo Sun Mining Corp. Begins Trading on OTCQX
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- Belo Sun Mining Corp. (“Belo Sun” or the “Company”) (TSX: BSX; OTCQX: BSXGF) is pleased to announce that effective today, its common shares have qualified to ...